Blog

Deepak Bhatt: How AI, Precision Medicine, and Innovative Therapies Are Shaping the Future of Oncology

Collage photo of Deepak Bhatt and Matthew Kurian

Oct 19, 2024, 16:45

Deepak Bhatt: How AI, Precision Medicine, and Innovative Therapies Are Shaping the Future of Oncology

Deepak Bhatt, Founder and CEO of Global Management Consultancy, shared on X:

“We are thrilled to welcome Dr. Matthew Kurian in today’s episode! He’ll dive into ‘Transforming Cancer Care: How AI, Precision Medicine, and Innovative Therapies Are Shaping the Future of Oncology.’

Dr. Kurian is a hematology/oncology physician at St. Elizabeth and Assistant Professor at UKY Medicine, specializing in breast and genitourinary cancers. With expertise in radioligand therapies like Lu-177, his insights are invaluable!”

Deepak Bhatt is the Founder and CEO of Global Management Consultancy, where he leads initiatives focused on driving organizational growth and employee success. In addition to his role at Global Management, he serves as a Business Consultant for BW Businessworld Media Private Limited, specifically for the Gujarat region.

With over 18 years of experience in the industry, Deepak excels at catalyzing both individual and organizational achievements, leveraging his expertise to enhance productivity and foster a culture of success. His commitment to developing effective strategies has made a significant impact on the organizations he collaborates with.

Matthew Kurian is a staff hematology/oncology physician at St. Elizabeth Healthcare and an assistant professor of medicine at the University of Kentucky College of Medicine. His primary focus lies in breast and genitourinary (GU) cancers, where he combines clinical practice with research to improve patient outcomes.

Dr. Kurian has expertise in radioligand treatments, including Lu-177, and has published several peer-reviewed articles on various oncology topics. He completed his oncology fellowship at the NCI-designated University Hospitals/Case Comprehensive Cancer Center, where he also served as the Chief Fellow of the Hematology/Oncology Fellowship Program for the 2022-2023 academic year.